Compare Adaptive Biotechnologies Corp (ADPT) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Avantis US Small Cap Value ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Avantis US Small Cap Value ETF trades at $127.31. Which is the better fit depends on your goals.
| ADPT | AVUV | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $128.74 |
52-Week Low | $12.30 | $93.93 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
AVUV trades at $127.03, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend with moving averages strongly supporting upside momentum while oscillators remain neutral. The ETF has attracted significant attention for its small-cap value exposure, with recent articles highlighting its strong performance relative to broader small-cap indices and its role in diversifying tech-heavy portfolios.
Outlook remains positive as small-cap value continues outperforming growth stocks in 2026. Investment opportunity lies in continued rate cut expectations and regional bank exposure driving returns. Key risks include sensitivity to interest rate changes, higher volatility typical of small-caps, and concentrated US market exposure limiting global diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
